AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT02713139 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Metronidazole
Description: Vaginal gel with Metronifdazole 100mg/g. Apply once per day, before bedtime, for 10(ten) days.
Study NCT02713139 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Clotrimazole
Description: Vaginal cream with Clotrimazole 20mg/g. Apply once per day, before bedtime, for 3 (three) days.
Study NCT03349632 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: verofilcon A contact lenses
Description: Investigational spherical silicone hydrogel contact lenses for daily disposable wear
Study NCT03349632 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: senofilcon A contact lenses
Description: Commercially available spherical silicone hydrogel contact lenses for daily disposable wear
Study NCT03349632 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: stenfilcon A contact lenses
Description: Commercially available spherical silicone hydrogel contact lenses for daily disposable wear
Study NCT03349632 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: etafilcon A contact lenses
Description: Commercially available spherical silicone hydrogel contact lenses for daily disposable wear
Study NCT03369132 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Angiflash
Description: throat spray (20 ml) containing hypertonic seawater, vegetable glycerin, natural mint, acacia honey, propolis extract, essential oils of thyme linalool, ravintsara and wintergreen, natural lemon flavor.
Study NCT03369132 — intervention group
Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: water based throat spray matching Angiflash for posology, dispensed volume, shape and size.
Study NCT03326167 — intervention group
Intervention type: OTHER
Intervention: Myocardial Perfusion Imaging by Single Photon Emission Computed Tomography (MPI SPECT)
Description: Evaluation of the improvement of the sensitivity, in tri-truncular patients, provided by the estimation of the coronal reserve by territory, during the realization of a myocardial perfusion tomoscintigraphy on CZT camera dedicated to cardiology (Discovery NM 530 ).
Study NCT00697619 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Zometa (zoledronic acid)
Description: Zometa 4 mg IV infusion every 4 weeks for 24 months. Co-administration with Zometa: Calcium 500 mg + vitamin D 400-500 IU daily
Study NCT03324815 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Morphine
Description: Pain Treatment
Study NCT03324815 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Methadone
Description: Pain Treatment
Study NCT01940445 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: M22 ResurFX
Description: Fractional NA treatment (ResurFX) on one side of the face
Study NCT01940445 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: M22 ResurFX and QS
Description: Fractional NA treatment followed by QS laser treatment (SST) on one side of the face
Study NCT03224624 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: self-management protocol for hypertension care
Description: participants in this arm will be taught to monitor and record their blood pressure. On a regular basis they will evaluate their blood pressure record and follow an algorithm to decide whether to adjust their medication.
Study NCT02375945 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: New non-elastic compression kit
Description: Comparison of new non-elastic bandage kit with the currently accepted method
Study NCT02375945 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: New non-elastic compression kit
Description: Comparison of new non-elastic bandage kit with the currently accepted method
Study NCT02375945 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: current compression stocking Comprinet®
Description: Comparison of new non-elastic bandage kit with the currently accepted method
Study NCT02375945 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: current compression stocking Comprinet®
Description: Comparison of new non-elastic bandage kit with the currently accepted method
Study NCT02248012 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Everolimus , temozolomide
Study NCT04232540 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: MedViewer report
Description: Results from the analysis of hair samples performed using the MedViewer
Study NCT02378909 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Electrical stimulation device.
Description: In the intervention group, all participants will receive Geko device which will produce electrical stimulation to enhance wound healing. This is the non- invasive device, self adhesive, light and does not restrict the patient's movement. Wound will be measured at the beginning of the study (before the device is applied) and after the study is complete. Blood and wound tissue samples will also be taken pre and post electrical stimulation to observe the effect of electrical stimulation on wound healing in people with diabetes.
Study NCT01285076 — intervention group
Intervention type: OTHER
Intervention: Other: Retrospective chart review; one participant encounter visit.
Description: Participants will be selected based on medical record review in the office of their treating cardiologist, nephrologist, neurologist, or family practice doctor. Participants will have one encounter visit to fill out questionnaires and have a blood draw and recording of weight, blood pressure and waist circumference.
Study NCT02926755 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Coronary Angiography
Description: Coronary angiography which includes fractional flow reserve (FFR),that allows precise measurement of blood flow in the arteries to the heart; the Near Infra-Red Spectroscopy-Intravascular Ultrasound (NIRS IVUS) provides information about the amount of lipid and cholesterol in the plaque, and plaque volume;the Optical Coherence Tomography (OCT) allows physicians to assess tears in the surface of plaque and plaque thickness; and Coronary CT Angiography (CCTA) to evaluate plaque characteristics, and correlate with the invasive findings. The research portion of the study requires all imaging studies be performed (NIRS, IVUS, OCT, FFR) during coronary angiography, rather than just one or two of these imaging studies, and the CCTA.
Study NCT01611896 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Selenium
Description: 100 µg tablets. The dose of daily supplement of selenium is set at 200 µg (two tablets). The duration of the intervention period is between 24-30 months. This is defined by the time of ATD treatment withdrawal, which is scheduled between approximately 12-18 months after randomisation. Selenium supplementation will continue 12 months after withdrawal of ATD treatment.
Study NCT01611896 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo tablets, identical in regards to size, appearance, taste, smell, and solubility to the experimental intervention tablet will be produced by Jemo-Pharm A/S, http://www.jemo-pharm.dk/frame.cfm/cms/id=977/sprog=2/grp=6/menu=1/ (content as in section: Auxiliary agents). The placebo regimen will be identical to the selenium regimen, but consist of two non-active tablets per day for 24-30 months.
Study NCT04045015 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Liqourice
Description: Liqourice corresponding to 1.5, 3.0 or 6.0 mg glycyrrhizic acid per kg body weight is taken in the evening during 7 days.
Study NCT02877537 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Salbutamol
Description: bronchodilation obtained with 2 inhalations of salbutamol (100 µg per dose) with inhalation chamber
Study NCT01394133 — intervention group
Intervention type: DRUG
Intervention: Tenofovir, Emtricitabine, Atazanavir, Ritonavir
Description: Women will be receiving Tenofovir 300mg, Emtricitabine 200mg, Atazanavir 300mg, Ritonavir 100mg, one dose on 2 separate visits. These medications will not be prescribed from the physician and not provided by the study.
Study NCT03867773 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Time restricted feeding
Description: TRF subjects will consume food ad libitum during the feeding window (4-h or 6-h window), and refrain from eating during the fasting window (20-h or 18-h window)
Study NCT01992094 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: QIVc
Description: Novartis Investigational Quadrivalent Vaccine
Study NCT01992094 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: TIV1c
Description: Licensed Influenza Vaccine
Study NCT01992094 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: TIV2c
Description: Novartis Investigational Vaccine
Study NCT00225641 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: CT-scan, CEA, X-ray of lungs
Description: Arm 1: 6, 12, 18, 24 and 36 months after surgery
Study NCT00225641 — intervention group
Intervention type: PROCEDURE
Group type: OTHER
Intervention: CT-scan, CEA, X-ray of lungs
Description: Arm 2: 12 and 36 months after surgery
Study NCT03114345 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Measurement of interface pressure
Description: A capacitive pressure mapping device (XSensor) is set up on the patient air mattress bed. It records the interface pressure on the whole patient body with one frame every second during one hour. Then the file is saved and the pressure mapping device is removed from the patient hospital bedroom.
Study NCT03992482 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Normal Saline Eye Drops (0.9% NaCl) two times a day for eight weeks
Study NCT03114345 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Measurement of micro-vascularization related parameters
Description: A medical device called O2C, measuring micro-vascularization related parameters (oxygen saturation, hemoglobin quantity and blood flow) is used. The probe (= an optic fibre) is set up lightly on the patient skin or on a transparent adhesive for 1 minute. The median value of the local micro-vascularization parameters are saved on the O2C interface. The location of the measurement is chosen using the pressure mapping device to locate peak pressure area. Then the O2C is removed from the patient hospital bedroom.
Study NCT04795869 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Brentuximab Vedotin
Description: Given IV
Study NCT04795869 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Pembrolizumab
Description: Given IV
Study NCT02451696 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Everolimus
Description: This study will measure if the drug called Everolimus effects mTOR signaling (an electrical activity signal in the brain) in patients with Tuberous Sclerosis Complex (TSC) and Focal Cortical Dysplasia (FCD) with treatment resistant epilepsy (TRE) who will be undergoing brain surgery. One group of patients will be treated with Everolimus, for 7-28 days prior to epilepsy surgery and another will not. We will determine if there is a difference in mTOR signaling between the patients who were treated with Everolimus and those who were not
Study NCT00351117 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: St. John's Wort
Description: SJW in capsule form 300 mg PO TID
Study NCT00351117 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Lactose
Description: lactose in gelatin capsule that same as St. John's wort
Study NCT01686217 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ASP015K ER
Description: oral extended release (ER) at three dosing levels
Study NCT01686217 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: ASP015K IR
Description: oral immediate release (IR)
Study NCT02877537 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Forced oscillation technique
Description: before and after bronchodilation
Study NCT01214239 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: once a day
Study NCT01214239 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Linagliptin
Description: once a day
Study NCT01816789 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: rFSH
Study NCT01816789 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: rFSH
Study NCT01816789 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: buserelin
Study NCT04454996 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: The placebo of Chang 'an II Recipe
Description: This is a granule containing 5% chang 'an II,1 bag each time, 3 times a day, treatment for 4 weeks.
Study NCT01816789 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: buserelin
Study NCT00834613 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Glucophage® XR 750 mg Tablets
Description: 1 x 750 mg, single-dose fed
Study NCT03793816 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: BiZactTM Open Sealer/Divider
Description: The BiZactTM Open Sealer/Divider creates a seal by application of radiofrequency (RF) electrosurgical energy to blood and lymphatic vessels or tissue bundles interposed between the jaws of the instrument. A cutting blade within the instrument is surgeon-activated to divide tissue. It is a single-use device and will not be reused in other patients.
Study NCT00834613 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Metformin ER 750 mg Tablets
Description: 1 x 750 mg, single-dose fed
Study NCT00686868 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: placebo
Study NCT00686868 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ofatumumab
Description: fully human anti-CD20 monoclonal antibody
Study NCT01164540 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rosuvastatin (AZD4522)
Description: Oral dose (od) 20 mg
Study NCT01164540 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Oral dose (od)
Study NCT03310827 — intervention group
Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Personalized Nutrition
Description: Diet plan based on nutrition-related gene test results
Study NCT03310827 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Personalized Nutrition
Description: Diet plan based on nutrition-related gene test results
Study NCT03176758 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Spinal Block
Description: Intrathecal 10 mg Heavy Marcaine, 200 mcg Morphine + High volume local anesthesia infiltration Bupivacaine 5mg/ml + adrenaline 5 mcg/ml 3mg/kg IBW diluted with 100cc Normal Saline
Study NCT03176758 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: General anesthetic
Description: 1-3 mg IV propofol 0.5 mg/kg IV Rocuronium + Fentanyl 2-3 mcg/kg + Morphine 0.1mg/kg IV Maintenance: Volatile anesthetic + High volume local anesthesia infiltration Bupivacaine 5mg/ml + adrenaline 5 mcg/ml 3mg/kg IBW diluted with 100cc Normal Saline
Study NCT02328040 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo and Insulin monotherapy via CL
Description: In the control arm patient receives a placebo pill with the closed loop with insulin/novolog (placebo and insulin/novolog via CL)
Study NCT02328040 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Sitagliptin and insulin/novolog via CL
Description: In the treatment arm the participant receives a single dose of sitagliptin with closed loop with insulin/novolog (Sitagliptin and insulin/novolog via CL), Part B
Study NCT03214237 — intervention group
Intervention type: OTHER
Intervention: no intervention - cross-sectional observational only
Description: no intervention - cross-sectional observational only
Study NCT03328390 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Quadratus lumborum block
Description: 15 ml of 0.5% isobaric bupivacaine + 10 ml saline + 50 micro gram dexmedetomidine + epinephrine (1:100,000) for each side.
Study NCT03328390 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Transversus abdominis plane block
Description: 15 ml of 0.5% isobaric bupivacaine + 10 ml of saline + 50 micro gram dexmedetomidine + epinephrine (1:100,000) for each side.
Study NCT00486993 — intervention group
Intervention type: BEHAVIORAL
Intervention: Dietary and nutritional modification
Study NCT00486993 — intervention group
Intervention type: BEHAVIORAL
Intervention: Stop smoking
Study NCT00486993 — intervention group
Intervention type: BEHAVIORAL
Intervention: Regular physical activities
Study NCT00486993 — intervention group
Intervention type: BEHAVIORAL
Intervention: Weight reduction to normal ranges
Study NCT00486993 — intervention group
Intervention type: BEHAVIORAL
Intervention: Regular intake of polyphenols, esp. from Ilex paraguayensis
Study NCT01326351 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Regenerative injection therapy
Description: Injection of 10cc of a 15% dextrose and 0.6% lidocaine solution free of epinephrine in one injection site (lateral infiltration of the plantar fascia). This injection will be performed following posterior tibial nerve blockade (injection of 10cc of 1% lidocaine and 0.25% bupivacaine solution free of epinephrine behind the posterior tibial artery). The intervention will be administered every three weeks until symptoms are alleviated for a maximum of 5 injection sessions. Furthermore, patients must perform an at-home exercise program 3 times a week for a total of 12 weeks. The exercise program consists of 3 stretching exercises, 1 muscle release exercise and 1 strengthening exercise.
Study NCT01326351 — intervention group
Intervention type: PROCEDURE
Group type: SHAM_COMPARATOR
Intervention: Dry needle injection
Description: Injection of dry needle in one injection site (lateral infiltration of the plantar fascia). This injection will be performed following posterior tibial nerve blockade(injection of 10cc of 1% lidocaine and 0.25% bupivacaine solution free of epinephrine behind the posterior tibial artery). The intervention will be administered every three weeks until symptoms are alleviated for a maximum of 5 injection sessions. Furthermore, patients must perform an at-home exercise program 3 times a week for a total of 12 weeks. The exercise program consists of 3 stretching exercises, 1 muscle release exercise and 1 strengthening exercise.
Study NCT01326351 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Exercise
Description: At-home exercise program that patients must perform 3 times a week for a total of 12 weeks. The exercise program consists of 3 stretching exercises, 1 muscle release exercise and 1 strengthening exercise.
Study NCT04161950 — intervention group
Intervention type: OTHER
Intervention: Assessment of the safety and validity of echoendoscope
Description: 1. Ultrasonic and endoscopic image quality assessment~2. Device controllability assessment~3. System safety assessment~4. System stability assessment
Study NCT04532996 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Trauma-focused psychodynamic psychotherapy
Description: This psychotherapy addresses disruptions in narrative coherence and affective dysregulation by exploring the psychological meanings of symptoms and their relation to traumatic events. The therapist works to identify intrapsychic conflicts, intense negative affects, and defense mechanisms related to the PTSD syndrome using a psychodynamic formulation that provides a framework for intervention. The transference provides a forum for patients to address feelings of mistrust, difficulties with authority, fears of abuse, angry and guilty feelings, and fantasies.~This treatment will be provided in-person or over teletherapy as the public health situation demands.
Study NCT00473616 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AZD7762
Description: intravenous infusion
Study NCT00473616 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Irinotecan
Description: intravenous injection
Study NCT00960154 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: PEAK PlasmaBlade
Description: The entirety of the lumpectomy will be performed with the PEAK PlasmaBlade including the skin incision
Study NCT00960154 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Traditional Electrosurgery with scalpel
Description: The skin incision will be performed using a standard scalpel; the subcutaneous dissection will be performed with traditional electrosurgery using the Cut and Coagulation modes.
Study NCT02786953 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Sleep Promotion
Description: Behavioral intervention to improve sleep quality and duration.
Study NCT00701194 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Early Intervention Foster Care (EIFC)
Description: The EIFC/MTFC-P intervention is delivered through a treatment team approach. Foster parents receive preservice training and ongoing consultation from program staff. Children receive individual therapy and attend a therapeutic playgroup. The intervention emphasizes the use of concrete encouragement for prosocial behavior; consistent, nonabusive limit-setting to address disruptive behavior; and close supervision of the child. The EIFC intervention employs a developmental framework in which the challenges of foster preschoolers are viewed from the perspective of delayed maturation and is oriented toward creating optimal environmental conditions to facilitate developmental progress. These conditions include a responsive and consistent caregiver and a predictable daily routine.